READ THE FULL REVB RESEARCH REPORT
Revelation Biosciences (NASDAQ:REVB) is a clinical-stage life sciences company focused on developing therapies that aim to strengthen and modulate the body’s innate immune response, with the goal of helping prevent or reduce the severity of infectious diseases. The company’s strategy centers on leveraging a platform designed to activate key immune pathways in a controlled way, potentially offering broad utility across multiple viral and bacterial threats rather than targeting only a single pathogen.
The company just released its year end 2025 financial report that showed the company with good cash on hand of $10.7 million, which is up from $6.5 million in the year-ago period, which is key for a clinical stage company. Company management believes that its current cash will be sufficient to fund operations into the first quarter of 2027. The company continues to be careful with its expenses and staying away from long-term debt, which we believe puts REVB in good financial shape for its continued push to get Gemini into the marketplace.
Gemini is the company’s primary treatment and is an intravenously administered treatment that reduces the damage associated with inflammation, which could be used in treating numerous conditions. The company recently announced that it has come to an agreement with the FDA on an approval pathway for Gemini as a treatment for Acute Kidney Injury (AKI). The agreement, in our view, will help to expedite the approval process as it features an adaptive design Phase 2/3 study, which allows Revelation to rapidly transition from Phase 2 to Phase 3. This is a crucial process as there are an estimated 34 million people, 34 million Americans, admitted to a hospital each year, and 20% of those had AKI (American Hospital Association). The only treatment we are aware of for severe ADI currently is dialysis, meaning Gemini is on track to be the first available treatment.
Additionally, Gemini is currently in a Phase 1b trial for chronic kidney disease (CKD), which approximately 37 million people are afflicted with. The company recently released data from its Phase 1 PRIME clinical study in stage 3 and 4 CKD patients. The primary endpoint to evaluate safety and tolerability of escalating doses was met.
But the major news from the study was that Gemini reduced inflammatory activity and restored normal cellular response. This demonstrates Gemini’s ability to durably rebalance the inflammatory process at the cellular level. This has implications for dozens of afflictions, such as CKD and burns, and makes the process toward commercialization more likely in our view. The statement from the Principal Investigator made us take additional notice as it was more positive than what we have often seen. Dr. Pablo Pergola, Research Director at Clinical Advancement Center, PLLC., noted, “The activity observed with a single dose of Gemini in patients is shocking. This effect suggests a meaningful step forward in addressing the underlying immune dysregulation observed in patients with chronic kidney disease, and I am intrigued by the potential of Gemini to treat multiple types of acute and chronic inflammation.”
Specifically, test results showed that in patients with high background PBMC activity, which are immune cells and can help be a measure of inflammation, Gemini significantly reduced inflammation relative to placebo patient PBMCs post dose and remained significantly below their baseline value through 7 days. Background inflammation was reduced to levels comparable to PBMCs isolated from healthy subjects. The importance of this cannot be overstated. Gemini is changing the cells and returning them to a normal state from the inflamed state, which treats the patient durably instead of just masking the symptoms. This ability has the potential to positively affect millions of patients suffering from CKD and other inflammatory diseases in a way that has been impossible to this point.
We are under no illusions that it’s easy to bring new therapies all the way to commercialization, but view these results as a significant step forward to that goal. As a result, we urge investors to use this opportunity to take in the above data and realize the potential Gemini has to positively impact lives and consider investing in REVB.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.
